Newcastle University – Confidence in Concept 2019
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Publications
Debelle H
(2023)
Feasibility and usability of a digital health technology system to monitor mobility and assess medication adherence in mild-to-moderate Parkinson's disease.
in Frontiers in neurology
Elshehabi M
(2022)
Walking parameters of older adults from a lower back inertial measurement unit, a 6-year longitudinal observational study.
in Frontiers in aging neuroscience
McDonald Claire
(2024)
A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults
in National Library of Medicine
| Description | "Dosing and Efficiency of Experimental Compounds Targeting TDP-43 Aggregation, Toxicity and Trans-synaptic Propagation in a Macaque Model of Amyotrophic Lateral Sclerosis. |
| Amount | £840,298 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2023 |
| End | 07/2026 |
| Description | Clinical Research Training Fellowship to Dr Amaani Hussain |
| Amount | £271,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 02/2027 |
| Description | GlycoScore: Superior prostate cancer diagnosis using a simple blood test |
| Amount | £150,000 (GBP) |
| Funding ID | NIHR202523 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 02/2022 |
| Description | Mobilise-D extension |
| Amount | £1,000,000 (GBP) |
| Organisation | Michael J Fox Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2022 |
| Description | Mobilise-D extension |
| Amount | £1,000,000 (GBP) |
| Organisation | Michael J Fox Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2022 |
| End | 11/2025 |
| Description | Personalised biologic treatment of psoriasis through biomarker integration and Artificial Intelligence-enabled mechanistic modelling of psoriatic plaque resolution |
| Amount | £150,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 03/2026 |
| Description | Senior Investigator award |
| Amount | £80,000 (GBP) |
| Funding ID | NIHR205039 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2027 |
| Description | Targeting GALNT7 to develop new drugs for the personalised treatment of prostate cancer |
| Amount | £513,099 (GBP) |
| Organisation | Prostate Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2022 |
| Description | Transforming Parkinson's disease clinical management with integrated digital health technologies |
| Amount | £500,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 07/2024 |
| Description | Walking-related mobility assessment in older people with multimorbidity |
| Amount | £93,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2024 |
| Description | Kinomica Ltd, Alderley Park - Support for CASE studentship applications |
| Organisation | Kinomica |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | MRC DiMeN student started 09/2022. Kinomica work in the phosphoproteomics space, providing services to pharma. They are interested in further validating our methodology because it could be used to expand the information content provided by their platform. |
| Collaborator Contribution | As above |
| Impact | Unknown at present |
| Start Year | 2022 |
| Description | New collaboration created to deliver on CiC project extension for data collection in additional 25 people with Parkinson's |
| Organisation | Sheffield Hallam University |
| Department | Active Orbit |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Link created as Aeqora ceased to exist, new collaboration created to deliver on CiC project extension for data collection in additional 25 people with Parkinson's |
| Collaborator Contribution | As above |
| Impact | New collaboration - no outputs as yet |
| Start Year | 2022 |
| Description | Participation in meetings, testing material provided by MIP Discovery |
| Organisation | MIP Diagnostics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have discussed licensing our technology with MIP Discovery and an upcoming paper. We also discussed the opportunity of evaluating new material by MIP Discovery, which will add impact to our platform since we can measure multiple markers. |
| Collaborator Contribution | As above |
| Impact | We are at the early discussion stages |
| Start Year | 2022 |
| Description | We are working with Attomarker to use our test on their platform |
| Organisation | Attomarker |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We commenced this collaboration so we could undertake our testing utilising their platform. |
| Collaborator Contribution | As above |
| Impact | No outputs to report at present |
| Start Year | 2022 |
| Description | We are working with Biorad to develop antibodies for our ELISA test |
| Organisation | Bio-Rad Laboratories, Inc |
| Department | Bio-Rad Laboratories Ltd. |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This collaboration was set up in August 2022 by the Project Team funding by CiC Project. Name of Project:- Care Pathway analysis and further validation for GlycoScore: a novel blood test for prostate cancer. Working to establish antibodies for our ELISA test |
| Collaborator Contribution | As above |
| Impact | No Outputs to report at present |
| Start Year | 2022 |
| Title | A rapid and field friendly detection of vitamin A deficiency using the i-RDR method |
| Description | Milestone 1: To identify the dose needed for the i-RDR method to detect isotope labelled retinol in finger prick samples - We have designed the study to test 2 different concentrations, of which the higher concentration is currently applied in the traditional MRDR test, which the iRDR test is aiming to replace. These concentrations were not tested in a human intervention trial at Newcastle University since vitamin A deficiency is extremely rare in UK participants. Instead, we are aiming to test traditional isotope concentrations in a pilot study performed in the Philippines, for which also total body stores of vitamin A will be determined. Dose response studies should ideally be performed, but this should be done first in a rat model, and then confirmed in a human intervention trial, for which larger funds are necessary. Milestone 2: Confirmation that finger prick blood samples can be used for the i-RDR method - The finger prick method was tested in a pilot study in Ghana, Africa as part of an ongoing Bill and Melinda Gates Foundation funded study. We have received over 300 samples from a field trial in the Philippines and are expecting a further 300 samples from another field trial in the Philippines in which this method was tested. The analysis of these samples in on-going. Milestone 3: Stability of isotope labelled retinol from finger prick samples under various storage conditions - This part of the study was carried out at Newcastle under strict environmental conditions testing 3 different storage conditions over a 3 months period. Data are currently analysed. Milestone 4: Application of the i-RDR method in LMIC settings - Two trials have been carried out in the Philippines between winter 2022 to winter 2023. Samples arrived in Newcastle in May 2023 and expect the final batch to arrive around spring 2024, with anticipated sample and data analysis completed by summer 2024. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2024 |
| Development Status | Under active development/distribution |
| Impact | Still in development stage |
| Description | A meeting with prostate cancer patients in Manchester to discuss our research |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Prostate Cancer Research meet the scientists day August 2022. Interaction with patients to discuss research on prostate cancer |
| Year(s) Of Engagement Activity | 2022 |
| Description | A panel discussion about the early diagnosis of prostate cancer with 150 audience members |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prostate Cancer UK The Panel meeting August 2022. Questions and Answer Session on topic. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Creation of dissemination video with CiC project overview |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Creation of dissemination video with CiC project overview (Collaboration with Master student - Oliver Latham). This video is promoting the CiC Project which looks at translating digital healthcare to enhance clinical management : evaluating the effect of medications on mobility in people with PD. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=CpUpVp1myhg |
| Description | Meeting 13/11/2023 with Mystheria to review funding applications / further experimental work. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Discussions are currently on hold pending results of follow-on spatial proteomics work as part of MRC/GSK EMINENT grant (ongoing). If data promising this could potentially contribute to further funding applications / experimental work to build case for repurposing of PIM inhibitors in immune mediated inflammatory diseases including inflammatory arthritis. There was an opportunity for questions and discussions afterwards raising further interest in the project work. |
| Year(s) Of Engagement Activity | 2023,2024,2025 |
| Description | Ongoing talks with Nevragenics Ltd regarding testing some of the nevragenics compounds in our model |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Newcastle CiC Project - CiC-Virus manufacture for primate models of neurodegenerative disease Nevrargenics Ltd is a local company that produces compounds that modulate retinic acid receptors, implicated in neurodegeneration. (Nevrargenics Ltd is a spin-out from Durham University (Prof Whiting is a CEO). A number of discussions have taken place with Nevragenics Ltd regarding testing some of the nevragenics compounds in our model and will be ongoing through 2025 for future activity. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Oral presentation of results of CiC study ' Translating digital healthcare to enhance clinical management' at the ICAMPAM Congress 2024 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation of results of CiC study ' Translating digital healthcare to enhance clinical management, evaluating the effect of medication on mobility in people with PD ' at the ICAMPAM Congress 2024. This gave attendees an opportunity to learn about the project, ask questions and share their experiences. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://iwcm-congress.com/ |
| Description | Oral presentation of results of CiC study 'Translating digital healthcare to enhance clinical management' at BioMedEng 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation of results of CiC study entitled 'Translating digital healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD' was given at the BioMedEng Conference 2023. As a result of the presentation, a number of questions and discussions took place triggering further interest in the project. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://biomedeng.org/biomedeng23/ |
| Description | Oral presentation to ISPGR World Congress on CiC Study (results of effect of medication on mobility in PD) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation of results of CiC study (effect of medication on mobility oin PD) at ISPGR World Congress 2023 (July 2023). There was an opportunity for questions and discussions afterwards raising further interest in the project work. The best clinical oral presentation was awarded to PhD student E Packer. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://ispgr.org/2023-congress/ |
| Description | Poster presentation at ISPGR 2022 World Congress on CiC protocol (July 2022) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation given by Project Leads for Translating Digital Healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD. Various questions were raised and the promotion of CiC Award given |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://ispgr.org/2022-congress/ |
| Description | Poster presentation at ISPGR 2022 World Congress on CiC review work |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presented by CiC Project Leads for: Translating Digital Healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://ispgr.org/2022-congress/ |
| Description | Presentation (Gordon Research conference) Innovative Approaches in Antibacterial Research & Development to fight resistance crisis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation at Gordon Research conference on Innovative Approaches in Antibacterial Research and Development to fight the antibiotic resistance crisis. There was an opportunity for questions and discussions afterwards raising further interest in the project work. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Presentation and discussion with Prostate Cancer UK North East Hub |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation and discussion with Prostate Cancer UK North East Hub around our research and ongoing work |
| Year(s) Of Engagement Activity | 2022 |
| Description | Presentation at BioMedEng Conference (8-9/09/2022) stemming from UG work and analysis on feasibility and usability data of the CiC project (poster) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presented by Project Leads of CiC Project - Translating Digital Healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD. Good questions were raised at the event and promotion of CiC gained. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://biomedeng.org/biomedeng22/ |
| Description | Presentation by PhD student E Packer of CiC study 'Translating digital healthcare to enhance clinical management' - Three Rivers Meeting 2024 (PD specialist meeting) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | A presentation was given by PhD student E Packer on the CiC study 'Translating digital healthcare to enhance clinical management' at Three Rivers Meeting 2024. The presentation was well received and sparked a number of questions and discussions during and after the presentation resulting in increased interest in the study. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://3riversnortheast.wordpress.com/ |
| Description | Presentation by PhD student E Packer. on CiC project 'Translating digital healthcare to enhance clinical management' at Parkinson's NEC-RIG event (PPIE) 2024 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation by PhD student E Packer on a CiC project 'Translating digital healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD'. This took place at the Parkinson's NEC-RIG event (PPIE) 2024. Questions and discussions took place both during and after the presentation was given. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://parkinsonsnec-rig.org/news-events |
| Description | Presentation to MNDA North-East Legacy Event (17/7/2024) - update on Project 'Virus manufacture for primate models of neurodegenerative disease' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | This was an opportunity for members of the Project Team at Newcastle to update our research to patients, families, carers and charitable donors affected by MND/ALS. During the event a number of questions and discussions which took place which in turn, increased interest in our work. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://newcastlemagazine.com/newcastle-hosts-special-event-on-groundbreaking-motor-neurone-disease-... |
| Description | Production of a video as an opportunity to gain insight into the development and optimisation of a sensor platform |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Production of a video that was showcased at a planned focus group which allowed us to have an opportunity to gain insight into the design of the proposed device |
| Year(s) Of Engagement Activity | 2023 |
| Description | Series of Presentations on results of CiC Project -Acipimox therapy to improve muscle function and sarcopenia through NAD enhancement. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | A series of presentations were given throughout 2024 to share the results of the Confidence in Concept Project entitled "Acipimox therapy to improve muscle function and sarcopenia through NAD enhancement using a precision medicine approach - feasibility and initial proof of concept". There was an opportunity for questions and discussions afterwards raising further interest in the project work. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Survey undertaken 300+ PD respondents worldwide to better understand medication adherence strategy & perception of digital health devices to help PD management |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | A Survey was created by colleagues involved in the CiC Project entitled 'Translating digital healthcare to enhance clinical management: evaluating the effect of medication on mobility in people with PD' The survey which was created, was successful with 300+ PD respondents from all over the world to better understand medication adherence strategy and perception of digital health devices to help PD management. The results were then used in several presentations throughout 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Work with Biorad to develop antibodies for ELISA test |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | We are working with Biorad to develop antibodies for our ELISA test |
| Year(s) Of Engagement Activity | 2022 |
| Description | Working with Attomarker to carry out testing on their platform |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | We are working with Attomarker to use our test on their platform |
| Year(s) Of Engagement Activity | 2022 |
| Description | Working with M2M to develop CE/A marked diagnostic kit |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Working with MedTech to Market (M2M) to develop our CE/A marked diagnostic kit |
| Year(s) Of Engagement Activity | 2022 |